SEARCH

SEARCH BY CITATION

References

  • Alhenc-Gelas, M., Jestin-Le Guiernic, C., Vitoux, J.F., Kher, A., Aiach, M. & Fiessenger, J.M. (1994) Adjusted versus fixed dose of low molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis, 71, 698702.
  • Backos, M., Rail, R., Baxter, N., Chilcott, I.T., Cohen, H. & Regan, L. (1999a) Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. British Journal of Obstetrics and Gynaecology, 106, 102107.
  • Backos, M., Rai, R., Thomas, E., Murphy, M., Dore, C. & Regan, L. (1999b) Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Human Reproduction, 14, 28762880.
  • Barbour, L.A., Kick, S.D., Steiner, J.F., LoVerde, M.E., Heddleston, L.N., Lear, J.L., Baron, A.E. & Barton, P.L. (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. American Journal of Obstetrics and Gynecology, 170, 862869.
  • Berndt, N., Khan, I. & Gall, R. (2000) A complication in anticoagulation using low-molecular weight heparin in a patient with mechanical valve prosthesis. A case report. Journal of Heart Valve Disease, 9, 844846
  • Blomback, M., Bremme, K., Helegren, M. & Lindberg, H. (1998) A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagulation and Fibrinolysis, 9, 343350.
  • Bounameaux, H. & De Moerloose, P. (2004) Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. Journal of Thrombosis and Haemostasis, 2, 551554.
  • Brenner, B. (2004) Clinical management of thrombophilia-related placental vascular complication. Blood, 103, 40034009.
  • Byrd, L.M., Johnston, T.A., Shiach, C. & Hay, C.R.M. (2004) Osteopenic fractures and low molecular weight heparin in pregnancy. Journal of Obstetrics and Gynaecology, 2451, S11.
  • Carp, H., Bardik, R., Lubetsky, A., Salomon, O., Eskaraev, R., Rosenthal, E. & Inbal, A. (2004) Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study. Human Reproduction, 19, 191195.
  • Casele, H.L., Laifer, S.A., Woelkers, D.A. & Venkataramanan, R. (1999) Changes in pharmacokinetics of the low molecular weight heparin enoxaparin during pregnancy. American Journal of Obstetrics and Gynecology, 181, 11131117.
  • Chamley, L.W., Duncalf, A.M., Mitchell, M.D. & Johnson, P.N. (1998) Action of anticardiolipin and antibodies to beta2-gylcoprotein-1 on trophoblast proliferation as a mechanism for fetal death. Lancet, 352, 10371038.
  • Chan, W.S., Anand, S. & Ginsberg, J.S. (2000) Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Archives of Internal Medicine, 160, 191196.
  • CLOT investigators (2003) Low molecular weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT study). The New England Journal of Medicine, 349, 109111.
  • Copplestone, J.A., Pavord, S. & Hunt, B.J. (2004). Anticoagulation in pregnancy. British Journal of Haematology, 124, 123125.
  • Dahlman, T.C. (1993) Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. American Journal of Obstetrics and Gynecology, 168, 12651270.
  • Dahlman, T.C., Sjoberg, H.E. & Ringertz, H. (1994) Bone-mineral density during long-term prophylaxis with heparin in pregnancy. American Journal of Obstetrics and Gynecology, 170, 13151320.
  • Dempfle, C.H. (2004) Minor transplacental passage of fondaparinux in vivo. The New England Journal of Medicine, 350, 19141915.
  • Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Services Northern Ireland (2000) Confidential Enquiries into Maternal Deaths in the United Kingdom 1997–9. Royal College of Obstetrics and Gynaecology, London.
  • Derksen, R.H.W.M, Khamashta, M.A. & Branch, D.W. (2004) Management of the obstetric antiphospholipid syndrome. Arthritis Rheumatism, 50, 10281039.
  • Di Simone, N., Caliandro, C., Castellain, R., Ferrazzani, S., De Carolis, S. & Caruso, A. (1999) Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Human Reproduction, 14, 489495.
  • Douketis, J.D., Ginsberg, J.S., Burrows, R.F., Duku, E.K., Webber, C.E. & Brill-Edwards, P. (1996) The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thrombosis and Haemostasis, 75, 254257.
  • Drife, J., Lewis, G. eds (2001) Why Mothers Die 1997–1999: Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. RCOG Press, London.
  • Ellison, J., Walker, I.D. & Greer, I.A. (2000) Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. British Journal of Obstetrics and Gynecology, 107, 11161121.
  • Empson, M., Lassere, M., Craig, J.C. & Scott, J.R. (2002) Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstetrics and Gynecology, 99, 135144.
  • Farquharson, R.G., Quenby, S. & Greaves, M. (2002) Antiphospholipid syndrome in pregnancy: a randomised, controlled trial of treatment. Obstetrics and Gynecology, 100, 408413.
  • Ginsberg, J.S., Greer, I. & Hirsh, J. (2001) Use of antithrombotic agents during pregnancy. Chest, 119, 122S131S.
  • Ginsberg, J.S., Chan, W., Bates, S.M. & Kaatz, S. (2003) Anticoagulation of pregnant women with mechanical heart valves. Archives of Internal Medicine, 163, 694698.
  • Girardi, G., Redecha, P. & Salmon, J.E. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine, 10, 12221226.
  • Glimelius, B., Busch, C. & Hook, M. (1978) Binding of heparin on the surface of cultured endothelial cells. Thrombosis Research, 12, 7382.
  • Greaves, M. (2002) Limitation of the laboratory monitoring of heparin therapy. Thrombosis and Haemostasis, 87, 163164.
  • Greer, I.A. (2002) Exploring the role of low-molecular-weight heparins in pregnancy. Seminars in Thrombosis and Hemostasis, 28(suppl. 3), 2531.
  • Gris, J.C., Quere, I., Monperyroux, F., Mercier, E., Ripart-Neveu, S., Taillar, M.L., Hoffet, M., Beraln, J., Daures, J.P. & Mares, P. (1999) Case–control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent – the Nimes Obstetricians and Haematologists study5 (NOHA5). Thrombosis and Haemostasis, 81, 891899.
  • Gris, J.C., Mercier, E., Quere, I., Lavigne-Lissalde, G., Cochery-Nouveellot Hoffet, M., Ripart-Neveu, S., Tailland, M.L., Dauzat, M. & Mares, P. (2004) Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood, 103, 36953699.
  • Haemostasis & Thrombosis Task Force (1993) Prevention, investigation and management of pregnancy-related thrombosis. Journal of Clinical Pathology, 46, 489496.
  • Hainer, J.W. Barrett, J.S., Assaid, C.A., Fossler, M.J., Cox, D.S. & Leathers, T. (2002) Dosing in heavy weight/obese patients with LMWH, tinzaparin: a pharmacodymanic study. Thrombosis and Haemostasis, 87, 817823.
  • Harenberg, J. (2004) Is laboratory monitoring of low-molecular-weight-heparin therapy necessary? Yes. Journal of Thrombosis and Haemostasis, 2, 547550.
  • Hirsh, J., O'Donnell, M. & Wietz, J.I. (2004) New anticoagulants. Blood, June 10th (e print ahead of pub).
  • Hull, R.D., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G. & McLaughlin, D. (1982) Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. The New England Journal of Medicine, 306, 16761681.
  • Hunt, B.J., Doughty, H., Majurndar, G., Copplestone, A., Kerslake, S., Buchanan, N., Hughes, G.R.V. & Khamashta, M.A. (1997) Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis and Haemostasis, 77, 3943.
  • Hunt, B.J., Gattens, M., Khamashta, M., Nelson-Piercy, C. & Almeida, A. (2003) Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagulation and Fibrinolysis, 14, 735739.
  • Hyers, T.M., Hull, R.D. & Weg, J.G. (1995) Antithrombotic therapy for venous thromboembolic disease. Chest, 108, 335351s.
  • Idir, M., Madonna, F. & Roudaut, R. (1999) Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical valve prosthesis during low-molecular weight heparin therapy. Journal of Heart Valve Disease, 8, 303304.
  • Kearon, C. (2003) Duration of therapy for acute venous thromboembolism. Clinics in Chest Medicine, 24, 6372.
  • Kelly, J., Humt, B.J. & Moody, A. (2003) Magnetic resonance direct thrombus imaging: a novel technique for imaging venous thromboemboli. Thrombosis and Haemostasis, 89, 773782.
  • Kupferminc, M.J., Eldor, A., Steinman, N., Many, A., Bar-Am, A., Jaffa, A. & Lessing, J.B. (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy. The New England Journal of Medicine, 340, 5052.
  • Kutteh, W.H. (1996) Antiphospholipid antibody-associated recurrent pregnancy loss treatment with heparin and low-dose aspirin is superior to low dose aspirin alone. American Journal of Obstetrics and Gynecology, 174, 15841589.
  • Lagrange, F., Vergnes, C., Brun, J.L., Paolucci, F., Nadal, T., Leng, J.J., Saux, M.C. & Banwarth, B. (2002) Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thrombosis and Haemostasis, 87, 831835.
  • Laude, I., Rongieres-Bertrand, C., Boyer-Neumann, C., Wolf, M., Mairovitz, V., Hugel, B., Freyssinet, J.M., Frydman, R., Meyer, D. & Eschwege, V. (2001) Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thrombosis and Haemostasis, 85, 1821.
  • Leizoroviecz, A., Bara, L., Samama, M.M. & Haugh, M.C. (1993) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis, 23, 8998.
  • Leizoroviecz, A., Haugh, M.C., Chapuis, F.R., Samama, M.M. & Boissel, J.P. (1992) Low molecular weight heparin in the prevention of peri-operative thrombus. British Medical Journal, 305, 913920.
  • Leizoroviecz, A., Simonneau, G., Decousus, H. & Boissel, J.P. (1994) Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: meta analysis. British Medical Journal, 309, 299304.
  • Lensing, A.W.A., Prins, M.H., Davidson, B.L. & Hirsh, J. (1995) Treatment of deep vein thrombosis with low molecular weight heparins. Archives of Internal Medicine, 155, 601607.
  • Lepercq, J., Conard, J., Borel-Derlon, A., Darmon, J.Y., Boudignat, O., Francoual, C., Priollet, P., Cohen, C., Yvelin, N., Schved, J.F., Tournaire, M. & Borg, J.Y. (2001) Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. British Journal of Obstetrics and Gynaecology, 108, 11341140.
  • Lev-Ran, O., Kramer, A., Gurevitch, J., Shapira, I. & Mohr, R. (2000) Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Annals of Thoracic Surgery, 69, 264265.
  • Mahesh, B., Evans, S. & Bryan, A.J. (2002) Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and review of options for anticoagulation. Journal of Heart Valve Disease, 11, 745750.
  • Marchetti, M., Pistorio, A., Barone, M., Serafini, S. & Barosi, G. (2001) Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. American Journal of Medicine, 111, 130139.
  • Merli, G., Spiro, T.E., Olsson, C.G. Abilgaard, U., Davidson, B.L., Eldor, A., Grigg, A., Musset, D., Rodgers, G.M., Trowbridge, A.A., Yusen, R.D. & Zawil, S. (2001) Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine, 134, 191202.
  • Monreal, M. (2000) Long-term treatment of venous thromboembolism with low-molecular weight heparin. Current Opinion in Pulmonary Medicine, 6, 326329.
  • Nelson-Piercy, C. (1997) Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clinical Obstetrics and Gynaecology, 11, 489509.
  • Nurmohamed, M.T., Rosendall, F.R., Buller, H.R., Dekker, E., Hommes, D.W., Vandenbrouke, J.P. & Briet, E. (1992) Low molecular weight heparin versus standard heparin in general and orthopaedic surgery. Lancet, 340, 152156.
  • Oles, D., Berryessa, R., Campbell, K. & Bhatti, M.A. (2001) Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion, 16, 159164.
  • Out, H.J., Kooijman, C.D., Bruinse, H.W. & Derkson, R.H.W.M. (1991) Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 341, 179186.
  • Pattison, N.S., Chamley, L.W., Birdsall, M., Zanderigo, A.M., Lideell, H.S. & McDougall, J. (2000) Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial. American Journal of Obstetrics and Gynecology, 183, 10081012.
  • Pettila, V., Leinonen, P., Markkola, A., Hilesmaa, V. & Kaaja, R. (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis, 87, 182186.
  • Preston, F.E., Rosendaal, F.R., Walker, I.D., Briet, E., Berntorp, E., Conard, J., Fontcuberta, J., Makris, M., Mariani, G., Noteboom, W., Pabinger legnani, C., Scharrer, I., Schulam, S. & van der Meer, F.J. (1996) Increased fetal loss in women with heritable thrombophilia. Lancet, 348, 913916.
  • Quinlan, D.J., McQuillan, A. & Wikelboom, J.W. (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. Annals of Internal Medicine, 140, 175183.
  • Rai, R.S., Cohen, H., Dave, M. & Regan, L. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal, 314, 253256.
  • Rey, E., Kahn, S.R., David, M. & Shrier, I. (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet, 361, 901908.
  • Roberts, N., Ross, D., Flint, S.K., Arya, R. & Blott, M. (2001) Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. BJOG, 108, 327329.
  • Rodie, V.A., Thomson, A.J., Stewart, F.M., Quinn, A.J., Walker, I.D. & Greer, I.A. (2002) Low molecular weight heparin, for the treatment of venous thromboembolism in pregnancy: a case series. BJOG, 109, 10201024.
  • Royal College of Obstetricians and Gynaecologists (1995) Report of the RCOG Working Party on Prophylaxis Against Thromboembolism in Gynaecology and Obstetrics. RCOG Press, London.
  • Royal College of Obstetricians and Gynaecologists (2004) Thromboprophylaxis During Pregnancy, Labour and After Vaginal Delivery. Guideline number 37. RCOG Press, London.
  • Sanderink, G.K., Liboux, A.L. & Jariwala, N. (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology and therapeutics, 72, 308318.
  • Sanson, B., Lensing, A.W.A., Prins, M.H., Ginsberg, J.S., Barkagan, Z.S., Lavenne-Pardonge, E., Brenner, B., Dulitzky, M., Nielsen, J.D., Boda, Z., Turi, S., Mac Gillavry, M.R., Theunissen, I.M., Hunt, B.J. & Büller, H.R. (1999) Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thrombosis and Haemostasis, 81, 668672.
  • Scholten, D.J., Hoedema, R.M. & Scholten, S.E. (2002) Comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obesity Surgery, 12, 1924.
  • Schulman, S. & Hellgrne-Wangdahl, M. (2002) Pregnancy, heparin and osteoporosis. Thrombosis and Haemostasis, 87, 180181.
  • Shefras, J. & Farquharson, R.G. (1996) Bone density studies in pregnant women receiving heparin. European Journal of Obstetrics, Gynecology and Reproductive Biology, 65, 171174.
  • Siragusa, S., Cosmi, B., Piovella, F., Hirsh, J. & Ginsberg, J.S. (1996) Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. American Journal of Medicine, 100, 269277.
  • Smith, J. & & Canton, E.M. (2003) Weight-based administration of dalteparin in obese patients. American Journal of Health-System Pharmacy, 60, 682687.
  • Spinler, S.A., Inverso, S.M., Cohen, M., Goodman, S.G., Stringer, K.A., Antman, E.M., ESSENCE & TMI Investigators (2003) Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. American Heart Journal, 146, 3341.
  • Topol, E.J. (2003) APPCR consensus panel. Anticoagulation with prosthetic cardiac valves. Archives of Internal Medicine, 163, 22512252.
  • Turpie, A.G. (2004) Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opinion on Pharmacotherapy, 5, 13731384.
  • Vitale, N., DeFeo, M., De Santo, L.S., Pollice, A., Tedesco, N. & Cotrufo, M. (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. Journal of the American College of Cardiology, 33, 16371641.
  • Vossen, C.Y., Preston, F.E., Conard, J., Fontcuberta, J., Makris, M., Van den Meer, G.J., Pabinger, I., Palareti, G., Scharrer, I., Souto, J.C., Svensson, P., Walker, I.D. & Rodsendaal, F.R. (2004) Hereditary thrombophilia and fetal loss: a prospective follow up study. Journal of Thrombosis and Haemostasis, 2, 592596.
  • Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M. & Kelton, J.G. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. The New England Journal of Medicine, 332, 13301335.
  • Weitz, J.L. (1997) Low-molecular weight heparins. The New England Journal of Medicine, 337, 688698.
  • Wheeler, A.P., Jaquiss, R.D.B. & Newman, J.H. (1988) Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Archives of Internal Medicine, 148, 13211325.
  • Wilson, W.A., Gharavi, A.E., Koike, T., Lockshin, M.D., Branch, D.W., Piette, J.C., Brey, R., Derksen, R.H.W.M, Harris, E.N., Hughes, G.R.V., Triplett, D.A. & Khamashta, M.A. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheumatism, 42, 13091311.
  • Wilson, S.J., Wilbur, K., Burton, E. & Anderson, D.R. (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low molecular weight heparin for the treatment of thromboembolism. Haemostasis, 31, 4248.
  • Yee, J.Y.V. & Duffull, S.B. (2000) The effect of body weight on dalteparin pharmacokinetics: a preliminary study. European Journal of Clinical Pharmacology, 56, 293297.
  • Young, E., Prins, M., Levine, M.N. & Hirsh, J. (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thrombosis and Haemostasis, 79, 117.